Cargando…
How to deal with steroids use in the management of metastatic prostate cancer during pandemic
Autores principales: | Baboudjian, Michael, Ploussard, Guillaume, Shariat, Shahrokh F., Ost, Piet, Briganti, Alberto, Roupret, Morgan, Pradere, Benjamin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475678/ https://www.ncbi.nlm.nih.gov/pubmed/32944516 http://dx.doi.org/10.21037/tau-20-1011 |
Ejemplares similares
-
The Use of Nonsteroidal Anti-inflammatory Drugs in Urological Practice in the COVID-19 Era: Is “Safe Better than Sorry”?
por: Pradère, Benjamin, et al.
Publicado: (2020) -
Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review
por: Laukhtina, Ekaterina, et al.
Publicado: (2021) -
Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature
por: Mbeutcha, Aurélie, et al.
Publicado: (2016) -
Chromogranin A: a useful biomarker in castration-resistant prostate cancer
por: Ploussard, Guillaume, et al.
Publicado: (2022) -
Intravesical therapy for bladder cancer in the pandemic of Covid-19
por: Teoh, Jeremy Y. C., et al.
Publicado: (2020)